North America Antacid Market Report

North America Antacid Market Size

The North America antacid market size was valued at USD 5.89 billion in 2025 and is estimated to reach USD 8.83 billion by 2034 from USD 6.16 billion in 2026, registering a CAGR of 4.6% from 2026 to 2034.

The rising prevalence of Gastroesophageal Reflux Diseases (GERD) is expected to impact the overall market over the forecast period. Furthermore, rising GERD awareness is expected to enhance the antacids industry. Therefore, dietary change is one of the primary elements likely to promote development during the projection period.

Heartburn's rising prevalence is also expected to impact the market over the forecast period. In addition, the availability of chewable tablets in various tastes aids patient medication adherence, which is projected to contribute to market expansion.

The rise of the antacid market in North America is primarily due to the rising prevalence of GERD and obesity. However, in low-income countries, a lack of understanding about gastrointestinal problems limits the Antacid market's growth.

Changing eating choices, a growing senior population around the world, a sedentary lifestyle, and an increase in gastroesophageal reflux disease are all factors driving the expansion of the North American antacid market.

Furthermore, the rising consumption of foods such as fried or fatty foods, citrus, chocolate, coffee, carbonated beverages, and other items that increase gastric HCl content in the stomach leads to antacid adoption, enhancing the market for antacids in North America.

Companies are reorganizing their operations and recovering from the pandemic, which had previously resulted in tight containment measures like social distancing, remote working, and the termination of commercial activities, making operations difficult and risky.

Antacid side effects are a significant stumbling block for the antacid market. Dose-dependent rebound hyperacidity and milk-alkali syndrome are two common antacid adverse effects.

However, the expanding number of antacid alternatives on the market and people's ignorance of acidity symptoms are likely to harm market growth.

REGIONAL ANALYSIS

Geographically, North America is predicted to be the most significant and fastest-growing regional market to rise as healthcare infrastructure improves and market actors raise their investments.

The U.S Antacid Market is predicted to rise rapidly due to the expanding geriatric population and lifestyle changes leading to gastrointestinal disorders among the American people. In addition, the growing trend toward self-medication is driving up demand for over-the-counter digestive products like antacids.

Antacids are the most commonly purchased OTC medications in the United States. This was ascribed to a rise in the occurrence of digestive disorders and increased consumer knowledge of antacid products.

The Canada Antacid Market is expected to reach significant growth during the period due to developed economies contributing to the development in the region.

The demand for antacids is driven by poor lifestyle choices, resulting in a higher prevalence of acidity. Poor lifestyle choices include desk work, poor sleep quality, and irregular food habits, all of which cause a rise in stomach acidity and lead to gastroesophageal reflux disease. This fuels the market for antacids in the region.

KEY MARKET PLAYERS

Some of the leading companies in the North American antacid market include

• GlaxoSmithKline plc
• Abbott Laboratories
• Pfizer, Inc.
• Sun Pharma
• Digene
• Pudin Hara (Dabur)
• Gelusil (Pfizer)

MARKET SEGMENTATION

This research report on the North American antacid market has been segmented and sub-segmented into the following categories.

By Drug Class 

• Proton Pump Inhibitors
• H2 Antagonist
• Acid Neutralizers
• Pro-motility Agents

By Formulation Type

• Tablet
• Liquid
• Powder

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Country

• The United States
• Canada
• Rest of North America